The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia

På svenska

Author

  • Anna Kreutzman
  • Taina Jaatinen
  • Dario Greco
  • Emmi Vakkila
  • Johan Richter
  • Marja Ekblom
  • Henrik Hjorth-Hansen
  • Leif Stenke
  • Teresa Melo
  • Ron Paquette
  • Ruth Seggewiss-Bernhardt
  • Agnes Guerci-Bresler
  • Alexis Talbot
  • Jean Michel Cayuela
  • Francois-Xavier Mahon
  • Kimmo Porkka
  • Jeff Lipton
  • Jukka Partanen
  • Philippe Rousselot
  • Satu Mustjoki
Show all

Summary, in English

Tyrosine kinase inhibitors have greatly improved the prognosis of chronic myeloid leukemia (CML). In addition to direct kinase inhibition, their effects can also be mediated through immune modulation, such as expansion of cytotoxic T and natural-killer cells observed during dasatinib therapy. As natural-killer cell and partially CD8(+) T-cell function are regulated by killer immunoglobulin-like receptors (KIRs), we studied whether the KIR gene profile is associated with clinical therapy response in dasatinib-treated CML patients (n = 191). In first-line patients, the absence of the inhibitory KIR2DL5A (p = 0.0489), 2DL5B (p = 0.030), and 2DL5all (p = 0.0272) genes were associated with improved molecular response at the 12-month time point. In addition, the same trend was seen with two activating KIR genes, 2DS1 (p = 0.061) and 2DS2 (p = 0.071). Furthermore, when patients were clustered into two groups by their KIR gene profile, the BCR-ABL1 transcript levels differed significantly between the groups (p = 0.047), showing that patients who lacked several KIR genes had better response. The comparison of first-line and second-line patients did not show any significant differences in either KIR or human leukocyte antigen genotypes. Our results show that immunogenetic factors, such as the KIR gene profile, can play a role in tyrosine kinase inhibitor therapy response. Additional studies are warranted to elucidate the functional significance of KIR genes associated with treatment outcomes. (C) 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.

Publishing year

2012

Language

English

Pages

906-913

Publication/Series

Experimental Hematology

Volume

40

Issue

11

Document type

Journal article

Publisher

Elsevier

Topic

  • Hematology

Status

Published

ISBN/ISSN/Other

  • ISSN: 1873-2399